A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)
- 29 October 2026
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Abstract
The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.Keywords
Funding Information
- National Federation of Health Insurance Societies
This publication has 13 references indexed in Scilit:
- Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa studyJapanese Journal of Clinical Oncology, 2024
- Cardiac Events and Survival in Patients With EGFR-Mutant Non–Small Cell Lung Cancer Treated With OsimertinibJAMA Network Open, 2024
- The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World PopulationJournal of Thoracic Oncology, 2024
- Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older (‘MONEY’ trial)Japanese Journal of Clinical Oncology, 2024
- Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLCJTO Clinical and Research Reports, 2024
- Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLCNew England Journal of Medicine, 2023
- Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung CancerThe Oncologist, 2022
- A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)Journal of Thoracic Oncology, 2021
- A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study)Japanese Journal of Clinical Oncology, 2020
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015